Abstract. Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.
INTRODUCTION
Mistakes in quality regularly appear in the news, often with disastrous consequences. In 1999, the Mars Climate Orbiter crashed due to a mix-up in measurement units. Scientists at Lockheed Martin built the orbiter assuming English units while NASA's Jet Propulsion Laboratory used metric units in their calculation of the orbiting process; this conflict in units resulted in an improper entry into the Mars atmosphere with the result being the loss of a $125 million orbiter. In relation to drug development, in 2010 Johnson and Johnson was forced to recall many different consumer products resulting in over $100 million in manufacturing plant remediation and loss of brand respectability by consumers and physicians alike when the Food and Drug administration reported various "inspectional deficiencies of varying degrees of seriousness at all of […their manufacturing] facilities". Fortunately, no deaths occurred. The same cannot be said when in 2007, five people died from eating accidentally contaminated spinach processed during a single shift in one food processing plant.
While there is no evidence that improper population pharmacokinetic-pharmacodynamic analyses have resulted in death or severe injury, these anecdotes were used to highlight the importance of quality and results that could occur when quality is ignored because as systems and processes become more and more complex, the potential for errors, mistakes, and oversights increases. Increased complexity in the presence of low quality leads to increased probability for failure. Because of this potential, organizations have been working to improve quality in recent decades. But defining quality is difficult. Quality standards may differ from individual to individual and from company to company. Quality control (QC) is thus an elusive concept. QC is sometimes used interchangeably with quality assurance (QA), but this is a mistake. QA is process oriented while QC is product oriented. QC does not ensure QA. For purposes of this manuscript, the focus will be on QC but even with this distinction, what consitutes quality will still be difficult to define.
Quality in relation to drug development has likewise played an increasing role in the last few decades to ensure data accuracy, data and study consistency, and fraud prevention. Quality standards are in place throughout the entire drug development process from formulation consistency in chemistry, manufacturing, and controls to clinical studies through good clinical practices (GCPs). In the data analytic fields, like statistics, formalized QC guidances or guidelines have not been issued by regulatory authorities although all companies put in place their own internal guidelines for QC through the issuance of standard operating procedures (SOPs).
Population analyses of pharmacokinetic and often pharmacodynamic data (PopPK-PD) in support of new drug applications and regulatory submissions are commonplace. The most commonly used program for such analyses is NONMEM, a Fortran-compiled program that reads ASCII files and performs modeling and simulation via a "control stream", which is a command line-like ASCII file of NONMEM-specific commands. On rare occasions, a small snippet of Fortran code is linked to the control stream which allows NONMEM to calculate some function it has not otherwise defined or some user-defined algorithm. After executing a control stream file, NONMEM generates a list file which summarizes the run and can optionally produce any number of ASCII tab-delimited output files that can be subsequently analyzed by a postprocessing program like R, SAS, MATLAB, S-Plus, or Sigmaplot (Fig. 1) . NONMEM is either executed from the command line/terminal emulator through DOS/Unix or via a so-called "front end" (like PDx-POP or Pirana (1)) that uses a graphical user interface and runs NONMEM in the background. Another commonly used program that runs from the command line is Perl Speaks NONMEM (PsN), which was designed to automate certain tasks (like bootstrapping and influence analysis) and perform computer-intensive statistical methods operations that early NONMEM versions do not perform (like calculation of conditional weighted residuals).
QC of data analytic processes encompasses two types of activities that are complementary to each other: verification and validation. Verification tests whether the model is programmed correctly and contains no errors, oversights, or bugs. Verification also ensures that the input data, the NONMEM control stream, and the output data are all grouped together as a unit. Validation relates to whether the model adequately reflects the observed data. The concept of model validation has been discussed in many papers (2-5) and will not be a focus of the QC process herein since validation is a matter of scientific review and opinion. The QC process presented in this manuscript will focus on model verification to the exclusion of model validation, although it must be understood that a credible model requires both validation and verification.
Different types of verification can be performed as part of the QC process and should be done at different times during the execution of the NONMEM analysis. This process is illustrated in Fig. 2 . Briefly, the first QC check should occur on the original source data, which should be checked not only for errors but also in terms of completeness of information required for the analysis. Upon fulfillment of the data requirements, the original source data can be used for the first transformation task (transformation task 1) which comprises the data management in order to create NONMEM input data files. A QC check here should also occur to determine whether the input data set is of the appropriate format and contains no errors. After development of the NONMEM model and/or performance of the simulations (transformation task 2), a QC check should occur on the NONMEM control streams, outputs, and listings. At this stage, a content review will take place to ensure that all activities have been performed according to the data analysis plan and that the end user, usually the project team, accepts the performed analysis. Upon acceptance, transformation task 3 occurs in order to generate a report which should be reviewed for quality and content. The QC check should include all NONMEM post-processing used to generate plots, tables, and listings added to the report. Finally, if data transfer to a regulatory body is expected to be necessary a last transformation function (transformation task 4) and subsequent QC check should occur in order to make sure that the data and reports fulfill regulatory requirements (6) .
If an error is found during any of the QC checks, the related transformation functions should be (partially or fully) repeated after the error is corrected, and a new QC check should be performed. This process should be repeated until all QC checks are passed. Ideally, all QC checks should be performed by a different pharmacometrician than the one performing the analysis. The first three tasks and the related quality checklists will now be discussed in turn. Transformation task 4 will not be discussed herein since this issue is discussed in regulatory guidances. Suffice it to say that it would be useful for sponsors to run the to-be-submitted dataset against the tobe-submitted NONMEM control stream to ensure that the same results are generated as previously reported.
TRANSFORMATION TASK 1 Data Analysis Plan
The data analysis plan (DAP) is a prospectively defined document that is a comprehensive and detailed description of the methods of pharmacokinetic-pharmacodynamic analysis (7) . The DAP should include a description of the data that will be used in an analysis, how the data will be handled (e.g., handling of missing data, handling of censored data, definition of outliers, etc.), the modeling methodology that will be used, and the reporting structure with mock tables, listings, and figures whenever possible. The DAP is similar in nature to a statistical analysis plan defined in the ICH E9 guidance that defines the objectives and methods of the statistical analysis of a clinical trial (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, (8) ). The same principles apply for the DAP-the objectives and methods of the modeling and simulation project should be clearly stated. The covariates that will be examined in the analysis should be explicitly detailed in the DAP, as well as the rationale for each covariate in the analysis. Model discrimination criteria should also be explicitly stated. For example, a forwards-backwards approach may be taken for covariate selection in which case the P value for covariate inclusion in the model and covariate exclusion in the model should be explicitly defined, usually 0.05 for inclusion and 0.01 for exclusion.
DAPs can be either add-on documents to protocols or standalone documents. Add-on DAPs are usually not as detailed as standalone documents as some parts of the DAP can be omitted, like a description of the study design. Standalone DAPs are usually multi-study analysis plans, but can be single study analysis plans as well. It is recognized that DAPs cannot fully envision every scenario, but they can be of sufficient detail to provide guidance and provide a reasonable level of assurance when followed appropriately. DAPs should be peer reviewed prior to any data analysis and should be reviewed with an eye towards the QC that will occur with the actual modeling.
NONMEM Input Data Files
Confirming that a NONMEM dataset is accurate is intimidating and some might say it's an impossible task for some multi-study phase 2/3 datasets with hundreds of subjects and thousands of observations. However, inaccurate data may lead to incorrect modeling results (as described by the cliche: "garbage in=garbage out"); thus, Fig. 2 . Schematic description of the transformation tasks related to the NONMEM analysis, including all steps that should be reviewed for quality (blue bars) and content (red bars). Every review step has its own checklist as described in the text QC of the data that will be modeled may be the single most critical step in the modeling process. Ideally one would confirm the dataset quality prior to any modeling but this may significantly delay the modeling process. Invariably there will be a period of analysis/modeling and correction of the NON-MEM dataset as mistakes are identified and rectified during the initial parts of the modeling process. For this reason, data QC is usually done during or after completion of the analysis, which is far from ideal as errors identified in the dataset may require reworking of part or all of the model development process. Hence, it may be useful to break the QC process into pieces: data specific processes could be tested during data merging, e.g., checking for units, consistency of dates and times, etc., then NONMEM-specific items can be tested, e.g., is the appropriate CMT value used for a compartment. Errors in the dataset can range from formatting, e.g., decimal numbers reported as integers, to dire errors where the wrong data are captured, e.g., the age of a patient from one study is merged with the identity of another patient from another study having the same patient identifier. NONMEM does some data checking as it reads the data file, e.g., it ensures that all dates and times are sorted within an ID, that a non-missing AMT is associated with a nonzero EVID, etc., but there are still many checks that it fails to do.
Some specific items that can be tested as part of the review process of the NONMEM input dataset are: -Are missing data handled as planned? (e.g., set to 0, imputed, etc.) -Are data records to be omitted (outliers, etc.) appropriately commented out and are they described in the report with the reason for omission? -Are concentrations below the limit of quantification appropriately handled (e.g., set to 0, set to half of LLOQ, imputed, etc.) as planned? It is important to distinguish between the properties a variable actually has and the properties it has in the NONMEM file (9), e.g., decimals are reported in fewer significant digits in the NONMEM dataset. The value of graphical analysis of data columns cannot be overstated. A histogram of a covariate data column can be used to detect outliers and groups with possibly inconsistent units.
For many NONMEM datasets a complete 100% QC of the dataset is an impossible task given available time and resources. A risk assessment should be undertaken to determine whether a complete data QC should be undertaken on some fraction of the data. For example, it may be decided that a complete data QC for a minimum number of randomly selected subjects per study in the dataset of the final model is sufficient.
TRANSFORMATION TASK 2
A framework for the QC of NONMEM analyses will now be presented. Because during the model development process, hundreds, if not thousands, of models can be tested and explored, it will be impossible to QC test each model due to time constraints. Therefore, QC will focus only on those models specifically discussed in the body of a report. Typically these include only two models: the base model without covariates and the final model with covariates. Additional models may sometimes be presented in the body of the report, but these can often be checked with an abbreviated QC checklist.
NONMEM Compiler and Third-Party Products
The type of NONMEM compiler that is used can impact the results of the analysis (10, 11 Like the NONMEM Input QC process, review of the NONMEM control streams can be saved for specific points during the analysis. For example after identification of the base model, all models used to develop the base model can be reviewed for correctness. Similarly, after covariate identification, all covariate models could be identified, and the same after identification of the final model.
NONMEM Listing
After executing a control stream, NONMEM generates a listing file summarizing its results. If $EST is used, the file will contain model parameter estimates and if $SIM is used, NONMEM will present a summary of the simulation. Results of a model specifically identified in a report should be compared to the listing for accuracy. Specific questions to be addressed include: 
Structure of the PopPK-PD Report
Both the Food and Drug Administration (7) and the European Medicines Agency (12) have guidelines for the overall report format of population analyses. The reader is referred to the original documents for details. Briefly, the final report subsections should include a summary, introduction, objectives, data, methods, results, and discussion section. There are no recommendations for the type of plots presented in the report using the FDA's guidelines, but there are recommendations in the EMA document. The report should comprehensively detail the analysis from data collection, database creation, model development, covariate selection, and model validation/evaluation. These results should then be placed in context in the discussion section of the report.
In a recent presentation, Edholm (13) & The report should be of sufficient quality such that "the final model can be judged to be a good description of the data in that the results and conclusions… can be considered valid."
Sponsors are expected to critically evaluate the quality of their model with regards to how well the model describes the observed data, what the limitations of the model are, what is the clinical relevance of the model covariates in their biological plausibility, how the results compared to previous analyses, and how will the results be used, e.g., to support labeling. Edholm also presented reasons for failing expectations which related to the quality of the report (primarily insufficient report detail, missing information, presentation of detailed but irrelevant information, analysis quality, and underlying data used to build the model) and to criticisms related to conclusions. A number of different case studies of reports of low quality were presented. In one case study, the assessor criticized the report for having no information on the number of samples excluded from the analysis for their concentrations being below the limit of quantification of the assay. Also criticized were the use of plots that relied on the Empirical Bayes Estimates of pharmacokinetic parameters when the degree of shrinkage was large (29% to 65%), that high concentrations were not captured in the visual predictive checks suggesting model misspecification, and that weight was used as a covariate in the model even though its inclusion did not result in a decrease of the objective function value. In another report from a different company, the model was criticized for not adequately capturing high concentrations and the report was criticized for not providing shrinkage estimates, for not showing the 5th, 50th, and 95th percentiles of the visual predictive check and for not stratifying by important covariates. Criticisms of the other analyses had to do with shrinkage, visual predictive checks, and insufficient information and detail.
Peer Review for Quality
Peer review of PopPK-PD reports is designed to guarantee that the displayed information is in agreement with the model listing and to ensure that the quality of the NONMEM analysis itself is satisfactory in terms of contents. Specific questions to be answered in relation to a specific model report are: 
Peer Review for Content
Peer review of population-related reports is a necessity as it helps the writer focus on strategy as well as the technical correctness of the document. Professional QC individuals and medical writers, while useful for inspecting the document for style and accuracy, are simply unqualified to evaluate the technical aspects of a population report. Peers with modeling experience, particularly with NONMEM-related experience and who are independent of the project, are required for part of the QC process. Peer review should focus on technical aspects of the document keeping in mind who the ultimate end users areregulatory authorities. Management should recognize that document review is an important and legitimate process, not something that needs to be tacked on top of one's other duties. The goal of a well-written and well-designed report is to put information in prominent locations, clearly address the issues, and to help reviewers quickly find the information they need.
NONMEM-based modeling reports are large and complex documents, sometimes as large as thousands of pages in length. The document, which is usually written by a single individual, may contain many tables, many figures, and can be verbose particularly with regards to the model development process. Document review in pharmaceutical companies typically takes the form of team review followed by managerial review. Because of the technical complexity of the modeling process, most team members and many managers are unqualified to evaluate the technical aspects related to the report. Although style and accuracy issues can be addressed, issues related to model development, evaluation, and analysis may be beyond their skills. Unfortunately, even technically qualified reviewers may not know how to properly review a document, nor have they ever been trained in that regard. Document review at the project team and managerial level tends to be informal. Individual document reviewers and teams tend to start at the beginning of the document and work their way towards the end. It is not uncommon to see far more suggestions, recommendations, and wordsmithing at the beginning of a document compared to the end of the document because by the time a reader gets to the end, they are often tired and want to finish. The same thing happens during roundtables where project teams focus so extensively at the beginning of the document that at the end of the meeting they realize that they never really reached the meat of the document and the meeting needs to be rescheduled.
McCulley/Cuppan LLC (14), a medical writing and communication consulting company, has presented some guidelines related to strategic review of documents that can be applied to modeling reports. (14) and Bernhardt (15) also provide additional guidelines for effective reviews. Peers should review reports from a technical point of view with the reader in mind and leave wordsmithing for medical writing professionals (though this may be necessary in some cases with difficult to read reports). Other guidelines include, but are not limited to:
& Once a section of a report has been reviewed (and subsequent corrections or improvements are made and approved), in future reviews make that section off-limits so that a "clean" section does not require further revision.
& Instead of starting a review at the beginning of a document, start at the methods section, or start at the results section to avoid comment condensation near the beginning of the document.
& Reports are often done after completion of the analysis.
Trying to write up the results sections days, weeks or sometimes months after completion is difficult. Authors should consider writing modeling reports in real time, even before the analysis is complete; objectives, study descriptions, demographics, basic methodology, etc., can all be prepared and placeholders for predefined tables and figures can be created. Upon the final analysis, the author simply needs to provide any additions to the prewritten sections, and insert the results, interpretation, and conclusions.
& Similarly, authors could consider having reviews done as report sections are completed, called staged review, rather than overwhelming reviewers with a single document at the end. Alternatively if modelers are unable to write reports in real time, a suggestion is to have a primary meeting with the team to simply discuss the final results and agree upon the message, conclusions, and implications.
& It is not uncommon to see a request from an author to reviewers that simply state something like "Please review this document by the end of the week". Rather than present reviewers with no guidelines for review except a due date, it may be possible to provide specific instructions for reviewers. For example, reviewers may be told to not focus on the mathematics or methodology but to focus on the document flow or interpretation. They may also be told that specific sections are still in draft form, i.e., not read for team review, or that specific sections do not require review.
& Reviewers should be trained in how to review and annotate documents and review with the user in mind. Comments, however, should be made with the author in mind. Simply putting comments like "please revise", "???", and "unclear" are in themselves unclear. Reviewers should add sufficient and specific detail to their comments such that the author will not have to come back to ask for clarification.
& Consider attaching a checklist to a review that asks for holistic comments. Comments made in the margins of a document are specific and local to a section. Too many reviewers focus on grammar and spelling. Reviewers should learn to make global comments and critiques that improve the overall quality of the document. An example of a global comment might be something like "The model showed that age affected clearance. There are not any graphs that really support this relationship."
& Instead of sending a copy of the document to everyone in a distribution list via e-mail, consider putting a single copy of the document out on a network drive or, ideally, in a version controlled system in which users must check out the document to edit it, then check it back in. In this manner, comments are entered in a cumulative manner with less likelihood for repetition, and version control is maintained. If this is not possible, to control having reviewers working on different versions of the document, each reviewer should send their version of the document with tracked changes to a single recipient (generally the author), and not to the entire team of reviewers. The author would then compile all comments, address what can be modified or clarified at that time, and then send out an updated version to all recipients at prespecified times.
In summary, strategic review asks whether the document makes the right arguments in the right place, whether its arguments are logically sound and well supported by the data, and whether a reviewer can quickly find such information. The goal is to develop a usable document that facilitates understanding.
Identified Errors
Errors are likely to be encountered in every NON-MEM-related project simply because of the complexity related to data merging, model development, reporting, and analysis. Errors can be of 3 types: errors related to models and model development, errors related to model analysis, and errors related to reporting of model results. Errors related to model development can range from the trivial like forgetting to include a $COV step to major, such as failure to identify a covariate associated with a pharmacokinetic parameter. Errors related to model development are difficult to spot particularly when modeling itself is such a subjective process; one modeler may choose one model over another but does this mean it was an error or a choice? Do differences in model parameters translate into a model error? Errors related to model analysis could be something like plotting PRED versus DV but labeling the plot as IPRED versus DV. Errors related to reporting model results can be inaccurate reporting of a model parameter value.
Errors identified during the QC process do not necessarily invalidate the results of a population analysis. Errors should be evaluated by the modeler as to the potential impact for affecting the final model and the model development process. Errors related to model development that are identified as minor (e.g., a single concentration value that is reported incorrectly) and unlikely to affect model results can be included in the body of the report as an addendum. Errors identified as major, e.g., a significant covariate having the wrong units for one study in a multi-study dataset, may necessitate rerunning some or all models in a modeling project. The modeler should identify the point in model development after which models should be rerun after error correction. Errors related to model analysis and reporting may require post-processing tables and figures be redone and the report updated accordingly. Again, the modeler's judgment should be exercised as to the degree to which analyses need to be repeated.
Regulatory Review of Population-Based Reports
The Food and Drug Administration (FDA) uses what is called a Question-Based Review (QBR) in their review of New Drug Applications (16) . FDA reviewers in the Office of Clinical Pharmacology are presented with a list of questions that they must answer as part of the review process. Questions include "What are the major intrinsic factors responsible for the intersubject variability in exposure (AUC, Cmax, Cmin) in patients with the target disease and how much of the variability is explained by the identified covariates?" or "Based upon what is known about [exposure-response] relationships in the target population and their variability, what dosage regimen adjustments are recommended for each group?" While there is no specific QBR template for review of population reports, guidances are available from regulatory authorities and within those guidances are recommendations for report format and structure. Authors should write their reports with an eye towards aiding the reviewer to answer the questions they must answer as part of their review and should include report elements as recommended in the regulatory guidances.
CONCLUSIONS
For the results of an analysis to be credible in the eyes of a reviewer, certain criteria need to be met. One of these criteria is report quality. Low report quality is associated with low model credibility. Formatting errors, typographical errors, poor grammar, reporting of wrong model file results, incorrect parameterization, or use of wrong data and graphics can consequently decrease the credibility of the model (and the modeler) in the eyes of the reviewer. A rigorous QC process will increase the readability of a report and allow the reviewer to focus on the details, issues, messages, and conclusions. Companies need to place greater emphasis on the review process as part of the clinical study and drug development process. Efficient QC and document review by companies will allow regulatory reviewers to more efficiently review regulatory submissions. While this paper has focused on the what and when to QC a population analysis, companies will have to decide for themselves how to implement these recommendations.
